NuclixBio develops early-stage nucleic acid therapeutics using proprietary platform technologies, including Circular mRNA and Aptamer-Drug Conjugates, for next-generation targeted treatments.
| Contact Details | 801, Digital-ro 33-gil 28, Guro-gu, Seoul 08377 Republic of KoreaTel. +82-2-6951-5893Email. nuclixbio@nuclixbio.com |
|---|
Find out more companies
Related products
-
-
-
-
VentureAprogen
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid
-
